{"id":38018,"date":"2025-07-28T15:10:25","date_gmt":"2025-07-28T07:10:25","guid":{"rendered":"https:\/\/flcube.com\/?p=38018"},"modified":"2025-07-28T15:10:26","modified_gmt":"2025-07-28T07:10:26","slug":"hengrui-and-gsk-enter-global-licensing-pact-for-pde3-4-inhibitor-hrs-9821","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=38018","title":{"rendered":"Hengrui and GSK Enter Global Licensing Pact for PDE3\/4 Inhibitor HRS-9821"},"content":{"rendered":"\n

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276<\/a>) announced on July 28, 2025, that it has entered into a collaboration, option, and licensing agreement with two intellectual property subsidiaries of GlaxoSmithKline (GSK; NYSE: GSK<\/a>). Under the agreement, Hengrui will grant GSK exclusive global rights to its PDE3\/4 inhibitor, HRS-9821, and an exclusive option for up to 11 preclinical-stage innovative projects, excluding mainland China, Hong Kong, Macau, and Taiwan.<\/p>\n\n\n\n

Financial Terms<\/strong>
Hengrui will receive an upfront payment of $500 million from GSK. The agreement includes significant milestone payments, with Hengrui potentially eligible for up to $12 billion if GSK exercises all options and achieves all development, registration, and sales milestones. Additionally, Hengrui will receive tiered sales royalties from GSK.<\/p>\n\n\n\n

HRS-9821: A Promising COPD Treatment<\/strong>
HRS-9821 is a potential best-in-class PDE3\/4 dual inhibitor currently in clinical development. It is designed for the maintenance treatment of chronic obstructive pulmonary disease (COPD), regardless of prior treatment history. Early studies have demonstrated significant bronchodilatory and anti-inflammatory effects, with potential for development as a dry powder inhaler.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced on July 28, 2025, that it…<\/p>\n","protected":false},"author":1,"featured_media":38020,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[65,16,278,184,2586,914,852],"class_list":["post-38018","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-auto-immune","tag-cancer","tag-glaxosmithkline","tag-gsk","tag-hengrui-pharmaceuticals","tag-nyse-gsk","tag-sha-600276"],"yoast_head":"\nHengrui and GSK Enter Global Licensing Pact for PDE3\/4 Inhibitor HRS-9821 - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced on July 28, 2025, that it has entered into a collaboration, option, and licensing agreement with two intellectual property subsidiaries of GlaxoSmithKline (GSK; NYSE: GSK). Under the agreement, Hengrui will grant GSK exclusive global rights to its PDE3\/4 inhibitor, HRS-9821, and an exclusive option for up to 11 preclinical-stage innovative projects, excluding mainland China, Hong Kong, Macau, and Taiwan.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=38018\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui and GSK Enter Global Licensing Pact for PDE3\/4 Inhibitor HRS-9821\" \/>\n<meta property=\"og:description\" content=\"China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced on July 28, 2025, that it has entered into a collaboration, option, and licensing agreement with two intellectual property subsidiaries of GlaxoSmithKline (GSK; NYSE: GSK). Under the agreement, Hengrui will grant GSK exclusive global rights to its PDE3\/4 inhibitor, HRS-9821, and an exclusive option for up to 11 preclinical-stage innovative projects, excluding mainland China, Hong Kong, Macau, and Taiwan.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=38018\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-28T07:10:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-28T07:10:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2809.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38018#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38018\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui and GSK Enter Global Licensing Pact for PDE3\\\/4 Inhibitor HRS-9821\",\"datePublished\":\"2025-07-28T07:10:25+00:00\",\"dateModified\":\"2025-07-28T07:10:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38018\"},\"wordCount\":180,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38018#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2809.webp\",\"keywords\":[\"Auto-immune\",\"Cancer\",\"GlaxoSmithKline\",\"GSK\",\"Hengrui Pharmaceuticals\",\"NYSE: GSK\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38018#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38018\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=38018\",\"name\":\"Hengrui and GSK Enter Global Licensing Pact for PDE3\\\/4 Inhibitor HRS-9821 - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38018#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38018#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2809.webp\",\"datePublished\":\"2025-07-28T07:10:25+00:00\",\"dateModified\":\"2025-07-28T07:10:26+00:00\",\"description\":\"China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced on July 28, 2025, that it has entered into a collaboration, option, and licensing agreement with two intellectual property subsidiaries of GlaxoSmithKline (GSK; NYSE: GSK). Under the agreement, Hengrui will grant GSK exclusive global rights to its PDE3\\\/4 inhibitor, HRS-9821, and an exclusive option for up to 11 preclinical-stage innovative projects, excluding mainland China, Hong Kong, Macau, and Taiwan.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38018#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38018\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38018#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2809.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2809.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hengrui and GSK Enter Global Licensing Pact for PDE3\\\/4 Inhibitor HRS-9821\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38018#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui and GSK Enter Global Licensing Pact for PDE3\\\/4 Inhibitor HRS-9821\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui and GSK Enter Global Licensing Pact for PDE3\/4 Inhibitor HRS-9821 - Insight, China's Pharmaceutical Industry","description":"China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced on July 28, 2025, that it has entered into a collaboration, option, and licensing agreement with two intellectual property subsidiaries of GlaxoSmithKline (GSK; NYSE: GSK). Under the agreement, Hengrui will grant GSK exclusive global rights to its PDE3\/4 inhibitor, HRS-9821, and an exclusive option for up to 11 preclinical-stage innovative projects, excluding mainland China, Hong Kong, Macau, and Taiwan.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=38018","og_locale":"en_US","og_type":"article","og_title":"Hengrui and GSK Enter Global Licensing Pact for PDE3\/4 Inhibitor HRS-9821","og_description":"China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced on July 28, 2025, that it has entered into a collaboration, option, and licensing agreement with two intellectual property subsidiaries of GlaxoSmithKline (GSK; NYSE: GSK). Under the agreement, Hengrui will grant GSK exclusive global rights to its PDE3\/4 inhibitor, HRS-9821, and an exclusive option for up to 11 preclinical-stage innovative projects, excluding mainland China, Hong Kong, Macau, and Taiwan.","og_url":"https:\/\/flcube.com\/?p=38018","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-28T07:10:25+00:00","article_modified_time":"2025-07-28T07:10:26+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2809.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=38018#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=38018"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui and GSK Enter Global Licensing Pact for PDE3\/4 Inhibitor HRS-9821","datePublished":"2025-07-28T07:10:25+00:00","dateModified":"2025-07-28T07:10:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=38018"},"wordCount":180,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=38018#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2809.webp","keywords":["Auto-immune","Cancer","GlaxoSmithKline","GSK","Hengrui Pharmaceuticals","NYSE: GSK","SHA: 600276"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=38018#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=38018","url":"https:\/\/flcube.com\/?p=38018","name":"Hengrui and GSK Enter Global Licensing Pact for PDE3\/4 Inhibitor HRS-9821 - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=38018#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=38018#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2809.webp","datePublished":"2025-07-28T07:10:25+00:00","dateModified":"2025-07-28T07:10:26+00:00","description":"China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced on July 28, 2025, that it has entered into a collaboration, option, and licensing agreement with two intellectual property subsidiaries of GlaxoSmithKline (GSK; NYSE: GSK). Under the agreement, Hengrui will grant GSK exclusive global rights to its PDE3\/4 inhibitor, HRS-9821, and an exclusive option for up to 11 preclinical-stage innovative projects, excluding mainland China, Hong Kong, Macau, and Taiwan.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=38018#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=38018"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=38018#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2809.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2809.webp","width":1080,"height":608,"caption":"Hengrui and GSK Enter Global Licensing Pact for PDE3\/4 Inhibitor HRS-9821"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=38018#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui and GSK Enter Global Licensing Pact for PDE3\/4 Inhibitor HRS-9821"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2809.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38018","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=38018"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38018\/revisions"}],"predecessor-version":[{"id":38021,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38018\/revisions\/38021"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/38020"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=38018"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=38018"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=38018"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}